Evidence map›Paper›PMID 40473272›Full record

ArticleJournal for immunotherapy of cancer2025

Enhancing antitumor immunity via ROS-ERS and pyroptosis-induced immunogenic cell death in multiple myeloma.

Liu Zhaoyun, Hao Wang, Chun Yang, Xianghong Zhao, Liu Hui, Jia Song, Kai Ding, Rong Fu

Abstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Liu Zhaoyun *Tianjin Medical University General Hospital, Tianjin, China furong8369@tmu.edu.cn liuzhaoyun114@163.com.ORCID http://orcid.org/0000-0002-2730-1562
Hao Wang *Tianjin Medical University General Hospital, Tianjin, China.
Chun YangTianjin Medical University General Hospital, Tianjin, China.
Xianghong ZhaoTianjin Medical University General Hospital, Tianjin, China.
Liu HuiTianjin Medical University General Hospital, Tianjin, China.
Jia SongTianjin Medical University General Hospital, Tianjin, China.
Kai DingTianjin Medical University General Hospital, Tianjin, China.
Rong FuTianjin Medical University General Hospital, Tianjin, China furong8369@tmu.edu.cn liuzhaoyun114@163.com.ORCID http://orcid.org/0000-0002-9928-9224

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFew studies have focused on the development of multiple myeloma (MM)-specific immunotherapies. Tumor immunogenic cell death (ICD), triggered by damage-associated molecular patterns, may enhance MM-specific antitumor activity, offering a potential treatment strategy.

methodsThis study confirms that combining reactive oxygen species (ROS)-endoplasmic reticulum stress (ERS) and pyroptosis-inducers (ROS-ERS inducer 1 (REI) and Quillaja saponaria fraction 21 (QS-21), respectively) activates specific anti-MM immunity. MM cell lines were treated with REI and QS-21 alone or in combination and cytotoxicity and apoptosis were examined. ICD markers were identified, including calreticulin, ATP, heat shock protein 70, and high mobility group box 1. Additionally, changes in mitochondrial damage, endoplasmic reticulum stress, pyroptosis markers, and immune markers of dendritic cell (DC) maturation and T-cell activation were assessed both in vitro and in vivo.

resultsROS-ERS combined with pyroptosis significantly induces MM cell apoptosis and enhances ICD marker activation. The combination treatment induces severe mitochondrial damage and endoplasmic reticulum stress, further promoting pyroptosis and MM-specific T-cell activation. In vivo, the combination treatment reduces tumor growth and improves DC and T-cell activation.

conclusionsThus, ROS-ERS inducers and pyroptosis inducers together significantly enhance the immunogenic response against MM, providing a promising strategy for MM treatment by activating powerful specific T-cell antitumor immunity.

Indexed as

Endoplasmic Reticulum StressImmunogenic Cell DeathMultiple MyelomaPyroptosisReactive Oxygen SpeciesAnimalsCell Line, TumorHumansMiceReactive Oxygen SpeciesImmunotherapyMultiple MyelomaT cell

Identifiers

PMID40473272
PMCPMC12142136

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.